GlassScriptPhysician profile
Emily P Gentry
NPI 1689007981
$2,219.36
in general payments reported to CMS, 2019-2025
24 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.37 · 2023: $125 · 2024: $936 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.77 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $323.56 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $276.69 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $135.16 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $125.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.84 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $110.93 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $106.52 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $73.46 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.00 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $50.36 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $43.20 | 2025 | Zoryve |
| Shield Therapeutics INC | $41.49 | 2024 | |
| Pfizer INC. | $38.62 | 2024-2025 | |
| Astellas Pharma US INC | $36.55 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $36.37 | 2021 | |
| Xeris Pharmaceuticals, INC. | $35.00 | 2024 | Gvoke Hypopen |
| Amgen INC. | $32.00 | 2024 | Otezla, Repatha |
| Boston Scientific Corporation | $24.29 | 2024 | |
| Medtronic, INC. | $20.16 | 2024 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $19.02 | 2025 | |
| Abbvie INC. | $18.03 | 2024 | |
| Axsome Therapeutics, INC. | $17.64 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.